Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer by Johansen Dagenborg, Vegard et al.
Frontiers in Oncology | www.frontiersin.org
Edited by:
Eyad Elkord,









†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Cancer Immunity and
Immunotherapy,
a section of the journal
Frontiers in Oncology
Received: 24 February 2021
Accepted: 03 May 2021
Published: 09 June 2021
Citation:
Dagenborg VJ, Marshall SE, Grzyb K,
Fretland AA, Lund-Iversen M,
Mælandsmo GM, Ree AH, Edwin B,
Yaqub S and Flatmark K (2021) Low
Concordance Between T-Cell
Densities in Matched Primary Tumors





published: 09 June 2021
doi: 10.3389/fonc.2021.671629Low Concordance Between
T-Cell Densities in Matched
Primary Tumors and Liver
Metastases in Microsatellite
Stable Colorectal Cancer
Vegar Johansen Dagenborg1,2,3, Serena Elizabeth Marshall 1, Krzysztof Grzyb4,
Åsmund Avdem Fretland5,6, Marius Lund-Iversen4, Gunhild Mari Mælandsmo1,7,
Anne Hansen Ree2,8, Bjørn Edwin2,6, Sheraz Yaqub2,5† and Kjersti Flatmark1,2,3*†
1 Department of Tumor Biology, Oslo University Hospital, Oslo, Norway, 2 Institute of Clinical Medicine, University of Oslo,
Oslo, Norway, 3 Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway, 4 Department of
Pathology, Oslo University Hospital, Oslo, Norway, 5 Department of Hepato-Pancreato-Biliary Surgery, Oslo University
Hospital, Oslo, Norway, 6 The Intervention Center, Oslo University Hospital, Oslo, Norway, 7 Institute of Medical Biology, The
Arctic University of Norway-University of Tromsø, Tromsø, Norway, 8 Department of Oncology, Akershus University Hospital,
Lørenskog, Norway
Background: The subtype, density and location of tumor infiltrating T-cells are being
explored as prognostic and predictive biomarkers in primary colorectal cancer (pCRC)
and colorectal liver metastases (CLM). Very limited data exist comparing findings in pCRC
and matched CLM.
Patients and methods: Fifty-eight patients with available pCRC and matched CLM (57/
58 microsatellite stable) were included in this OSLO-COMET substudy. In
immunohistochemically stained sections, total (Ttot), helper (TH), cytotoxic (CTL), and
regulatory (Treg) T-cells were manually counted in hotspots from the invasive margin (IM),
intratumor (IT), and tumor adjacent regions to determine T-cell densities.
Results: A striking accumulation of T-cells was found in IM of both pCRC and CLM with
much lower densities in the IT region, exemplified by Ttot of 2838 versus 340 cells/mm
2,
respectively, in CLM. The correlation at the individual level between T-cell densities in
pCRC and corresponding CLM was poor for all regions and T-cell subtypes; for instance,
the correlation coefficient (R2) for IM Ttot was 0.07. The IT TH : CTL and Treg : TH ratios
were 2.94 and 0.44, respectively, in pCRC, and 1.84 and 0.24, respectively, in CLM.
Conclusion: The observed accumulation of T-cells in the IM regions of pCRC and CLMwith
low penetration to the IT regions, combined with high TH : CTL and Treg : TH ratios, point to
the presence of an immune suppressive microenvironment. T-cell densities of CLM differed
markedly from thematched pCRC, indicating that to evaluate T-cell biomarkers in metastasis,
the commonly available pCRC cannot serve as a surrogate for the metastatic tumor.
Keywords: colorectal cancer, colorectal liver metastases, cytotoxic T cell, helper T cells, regulatory T cells, T cell
densities, tumor immune microenvironmentJune 2021 | Volume 11 | Article 6716291
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Colorectal cancer (CRC) is one of the most frequent cancers in
the western world and about 50% of CRC patients will develop
metastases during the course of disease, with the liver as the most
frequent metastatic site (1, 2). Surgery represents a curative
treatment option in approximately 25% of patients, but the
majority of patients are not eligible for surgical interventions
(3). Systemic chemotherapy now comprises a number of
cytotoxic and targeted agents that are administered
perioperatively, or as palliative treatment. Although the
therapeutic opportunities have improved dramatically over the
last two decades for patients with metastatic CRC (mCRC),
the successes derived from introduction of immunotherapy
have so far only been beneficial to microsatellite instable (MSI)
cases, comprising approximately 5% of patients with mCRC (4).
It is of high interest to understand the non-immunogenic
cancers, such as microsatellite stable (MSS) CRC, to potentially
identify opportunities to circumvent resistance and make
immunotherapy a therapeutic option for the majority of
mCRC patients (5). We recently showed up-regulation of
immune-related genes and increased T-cell infiltration in
colorectal liver metastases (CLM) after neoadjuvant
chemotherapy, suggesting that cytotoxic therapies might
favorably modify the tumor microenvironment to become
more immunologically active (6, 7).
The subtype, density, and location of tumor infiltrating T-
cells have been extensively investigated in primary CRC (pCRC),
and strong associations with prognosis have been convincingly
demonstrated (8–10), illustrating the importance of the adaptive
immune system in CRC progression. Emerging evidence also
suggests that patients with pCRC with a high density of T-cells
benefit the most from adjuvant chemotherapy (11). In resected
CLM, studies also point to an association between an abundance
of infiltrating T-cells in the metastatic tumors and a favorable
prognosis as well as response to chemotherapy (12–14). The
prognostic value of infiltrating T-cells in pCRC for the outcome
of subsequent CLM resection has been less extensively
investigated and show conflicting results (14, 15).
Studies of T-cell infiltration in pCRC and matched CLM are
heterogeneous with respect to cohort size, subtypes of T-cells
analyzed, study design and research focus. Three studies have
reported group comparisons of matched cases; one study showed
concordance (n = 24) (16), while two studies (n = 16 and 69) (17,
18) made discordant findings when comparing pCRC and CLM.
The only study where case-by-case correlation analyses were
performed was recently published and showed poor correlation
between the pCRC and CLM with respect to densities of CD3+
and CD8+ T-cells (n = 131) (14). Given the heterogeneity of
existing data and the potential usefulness of T-cell quantification
to portray the immune microenvironment in metastatic tumors,
further studies are warranted in the field. In the present study,
case-by-case and group analyses were performed to compare
pCRC to matched CLM. Densities of CD3+, CD8+, CD4+, and
FOXP3+ T-cells were analyzed using immunocytochemistry in a
cohort of 58 CRC (of which 57 were MSS).Frontiers in Oncology | www.frontiersin.org 2MATERIALS AND METHODS
Patients
Patients with resectable CLM were included in the Oslo
Randomized Laparoscopic Versus Open Liver Resection for
Colorec ta l Metas tases S tudy (OSLO-COMET tr ia l ,
NCT01516710) following informed consent (19). The study
was approved by the Regional Committee for Health and
Research Ethics in Norway (2011/1285/REK Sør-Øst B). All
patients had primary adenocarcinoma in the colon or rectum.
This OSLO-COMET sub study analyzed available samples from
the first 71 patients included in the trial between February 2012
and April 2013. Thirteen cases were excluded from analysis
because of unavailable or insufficient tumor content in the
pCRC (n = 6) and CLM sample (n = 7), leaving 58 patients with
pCRCtissue andcorrespondingCLM(bearing84metastases). In53
of 58 pCRC and all CLM samples tumor adjacent tissue was
evaluated. The pCRC was classified according to the TNM
classification (International Union Against Cancer TNM
classification 7th edition) (20). Performance status was classified
using the EasternCooperativeOncologyGroup score (ECOG). The
CLM clinical risk score (CRS) was calculated by giving 1 point for
the following parameters: lymph node metastases in pCRC, <12
months from pCRC to diagnosis of CLM, multiple metastases,
largest metastasis >5 cm, carcinoembryonic antigen (CEA) >200
µg/L. A CLM with CRS ≤ 2 was considered to have low risk of
recurrence (21). For patients who had neoadjuvant chemotherapy
prior to CLM resection, the response was classified using the
principles of Response Evaluation Criteria in Solid Tumor 1.1
(RECIST 1.1) (22).
Histological Assessment
Surgical specimens were formalin-fixed and paraffin embedded
(FFPE) as part of routine pathology processing, and one
representative tissue block was selected for analysis from each
of the 58 patients (pCRC and corresponding CLM). Three
regions were identified in hematoxylin and eosin (HE) stained
sections for T-cell quantification: the tumor adjacent region in
the colorectum and liver (NCr and NLi, respectively); the
intratumoural (IT) region and the invasive margin (IM).
Selections were confirmed by a pathologist.
T-Cell Densities Assessed by
Immunohistochemistry (IHC)
Four-µm sections were deparaffinized and pretreated using PT-
link, and subsequently stained using the Dako EnVision™ FLEX+
detection system (Agilent, California, USA). Serial sections were
stained for the total number of T-cells (Ttot - CD3 rabbit
monoclonal antibody; clone SP7; dilution 1:500, Thermo
Scientific, California, USA), CTL (CD8 Novocastra™
lyophilized mouse monoclonal antibody; clone 4B11; 1:200,
Leica Biosystems, Germany); helper T-cells (TH - CD4 mouse
monoclonal; clone 4B12; ready-to-use; DAKODenmark AS), and
regulatory T-cells (Tregs - Anti-FOXP3 antibody; clone 236A/E7;
dilution 1:400; Abcam, Cambridge, United Kingdom), all with
positive controls. The slides were digitized and within scannedJune 2021 | Volume 11 | Article 671629
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from both NCr and NLi tissue, three from the IT, and four from
the IM region, where possible. The areas were marked on the HE
slides, and the corresponding regions were located on serial
sections stained for detection of Ttot, CTL, TH and Treg. Due
to poor quality staining, the following sections could not be
evaluated: in NCr one sample of Ttot and one sample of CTL; in
pCRC TH in both IM and IT in the same sample. T-cells were
manually counted by investigator VJD who was blinded with
respect to patient characteristics at the time of T-cell
quantification. The T-cell density (cells/mm2) was calculated by
dividing the sum of T-cells counted with the total area (mm2)
selected within each region, using the Cell F software and an
Olympus BX51 microscope with a ×10/0.30 FN26.5 lens
connected to a XC30 camera. Immune cells were quantified
over a median area (min – max) in IM of 1.15 mm2 (0.99–
1.32) in pCRC and 1.14 mm2 (1.02–1.27) in CLM; in IT of 1.15
mm2 (1.13–1.16) in pCRC and 1.14 mm2 (1.07–1.22) in CLM;
0.76 mm2 (0.76–0.77) in NCr and 0.76 mm
2 (0.76–0.76) for NLi. A
total area of 1812 mm2 from all regions in both CRC and CLM
and normal tissue was used for immune cell quantification. An
area of 203 mm2 (11% of total area) from 26 tumor samples (10
pCRC and 16 CLM) was randomly selected from 16 patients for
validation (by investigator SEM). Linear regression analyses
comparing results by investigators VJD and SEM showed a
high correlation (R2 > 0.95) with no significant differences
comparing medians for each T-cell subtype.
Calculation of Immune Score
For pCRC and CLM, an immune score of 0 to 4 was calculated
using the method and cutoff values previously described by
Galon et al. (8). One point each was given for Ttot over cutoff
in IM (640 cells/mm2) and IT (300 cells/mm2), and 1 point each
for CTL densities over cutoff in IM (370 cells/mm2) and IT (80
cells/mm2). An immune score of 0 to 2 was considered low and 3
to 4 high.
Analysis of Microsatellite Instability (MSI)
The Idylla™MSI Assay from Biocartis (Mechelen, Belgium) was
used according to the manufacturer’s instructions to determine
whether tumors were MSS or MSI (23). In 35 of the 58 cases,
isolated DNA was available from CLM samples as previously
described (7), while in 23 cases, FFPE tissue was used [from CLM
resection sample (n = 20) or from the pCRC sample (n = 3)].
Statistical Analysis
The variables were described using percentages and median with
interquartile range (IQR) unless otherwise stated. Categorical
variables were created for the following parameters by using
medians as cutoff: age at pCRC resection, CEA levels at study
CLM resection, and T-cell densities. Ratios were calculated for
each tumor by dividing the following T-cell subtype densities:
TH : CTL and Treg : TH. Paired variables were compared using
Wilcoxon rank-sum test, independent variables by Mann-
Whitney U. Correlations between Ttot and subtypes (CTL, TH,
and Tregs) in pCRC and CLM, and NCr and NLi were analyzed by
linear regression. Results were reported with R2 values and P-Frontiers in Oncology | www.frontiersin.org 3values. Agreement between low or high immune score was
assessed by Cohen’s kappa coefficient. For analyses related to
outcome and immune score mean values were used for patients
with multiple metastases, as we previously demonstrated that the
variation in T-cell densities between metastases from the same
patients was very low (6). Overall survival (OS) was calculated
from pCRC resection to date of death (obtained from the
Norwegian National Registry) or censor date (31st December
2017). Progression-free survival (PFS) was calculated from the
time of study CLM resection to first event, last radiological
follow-up, or death. Univariable analyses were performed by
the Kaplan-Meier method to estimate OS and PFS. Reverse
Kaplan-Meier method was used to estimate median follow-up.
Hazard ratios (HR) were calculated using Cox proportional
hazard analysis and were reported with 95% confidence
interval (CI). A P-value < 0.05 was considered to be
statistically significant. Data were collated and analyzed using
IBM SPSS statistics software (version 25, IBM Corp,
Armonk, NY).RESULTS
Clinicopathological Variables
The 58 patients from the OSLO-COMET trial sub study had the
following clinicopathological features (Table 1): 32/58 (55%)
patients were male, with a median age of 66 (60–72) at diagnosis
of pCRC. The majority of patients had T3 or T4 pCRC (55/58;
95%), 34 patients (59%) had lymph node metastases in the pCRC
specimen, and the tumors were located in the left colon or
rectum in 42 cases (72%). Twenty-one cases (36%) had
radiological evidence of metastatic disease at the time of pCRC
diagnosis, and another 23 patients (40%) developed metastases
within 12 months after surgery for pCRC. The median time from
pCRC resection to diagnosis of CLM in the OSLO-COMET trial
was 7 months (0–16). At the time of CLM resection, 42 patients
(72%) were ECOG 0, 44 patients (76%) had a low CRS, and 28
patients (48%) had received neoadjuvant chemotherapy prior to
CLM resection, where the majority had response or stable disease
(24/28;86%). The median number of CLM was 1 (range, 1–6).
Only one case (1.7%) was classified as MSI.
The Highest T-Cell Densities Were
Detected in IM CLM
Examining the tumor adjacent tissues, the Ttot density in NCr was
double that of NLi (533 cells/mm
2 (371–764) versus 221 cells/
mm2 (122–319); P-value < 0.0001) (Figure 1, Table 2). The Ttot
densities of IT and NCr in pCRC were similar (P-value = 0.4),
comparatively, Ttot density of IT CLM was significantly higher
than NLi (340 cells/mm
2 (184–569) versus 221 cells/mm2 (122–
319); P-value < 0.0001). The highest density of T-cells was found
in IM of both pCRC and CLM, where IM CLM had more than
twice the density found in IM pCRC (2838 cells/mm2 (2292–
3841) versus 1244 cells/mm2 (933–1749); P-value <0.0001)
(Figure 1). Ttot density in IM CLM was 13-fold that quantified
in NLi.June 2021 | Volume 11 | Article 671629
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Both pCRC and CLM
The densities for the CTL and TH subtypes mirrored the Ttot
densities for all regions, with the highest CTL and TH densities
found in IM CLM followed by IM pCRC (Figure 1, Table 2). TH
was the dominating T-cell subtype in the tumor regions (IT and
IM) of both pCRC and CLM, with a median TH : CTL ratio of
more than one (Figure 2 and Supplementary Table 1). The
highest TH : CTL ratio was observed in IT pCRC (2.94 (1.70–
4.35) vs 1.84 (1.07–3.04)) in IT CLM, P-value < 0.001. Tumor
adjacent tissue had TH : CTL ratios close to or below 1 (1.16
(0.89–2.03) in NCr and 0.72 (0.44–1.14) in NLi). The TH : CTL
ratio (Figure 2) observed in IM pCRC and IM CLM were similarFrontiers in Oncology | www.frontiersin.org 4(1.71 (1.09–2.39) vs 1.83 (1.36–2.50), P-value = 0.4)
(Supplementary Tables 1, 2).
The Highest Treg/TH Ratios Were
Observed in IT pCRC
The densities of the Treg subtype were generally low in all analyzed
regions compared to CTL and TH (Table 2). Numerically, the
densities were higher in pCRC and NCr than in CLM and NLi, with
exception of the IM region where the Treg densities were
numerically similar in pCRC and CLM (Table 2). The Treg : TH
ratios were higher in the pCRC compared to corresponding CLM
regions (Figure 3 and Supplementary Table 2). The highest Treg :
TH ratio was observed in IT pCRC (0.44 (0.27–0.59)), nearly double
that found in IT CLM (0.24 (0.12–0.41), P-value < 0.0001). In IM
pCRC the Treg : TH ratio was 3 times higher than in IM CLM (0.33
(0.22–0.43) vs 0.11 (0.07–0.18); P-value < 0.0001) (Table 2). Similar
observations were made in the tumor adjacent regions, where Treg :
TH inNCrwas almost 10 times higher than inNLi 0.19 (0.14–0.25) vs
0.02 (0.00–0.08); P-value < 0.0001).
No Correlation Between T-Cell Densities
in pCRC and Matched CLM
The correlation between T-cell densities in pCRC and
corresponding CLM was poor for all regions, exemplified by
IM Ttot pCRC and CLM, R
2 = 0.07 (Figure 4, Supplementary
Table 3). Thirty-nine of 58 (67%) pCRC samples were scored to
have a high immune score (Table 1). When the same cutoff
values were applied to CLM, 34/58 (59%) were found to have a
high immune score. However, only 50% of pCRC and
corresponding CLM had a concordant score (i.e. high/high or
low/low; Cohen’s kappa coefficient = −0.6).
Associations Between Clinicopathological
Variables and Long-Term Outcome
The follow-up time after pCRC resection was an estimated
median of 79 months (95% CI: 67–91) and an estimated
median of 64 months (95% CI: 61–96) after CLM study
resection. Twenty-six (45%) patients died during follow-up.
After CLM resection the estimated 5-year OS was 58%, and
median OS was not reached. The median PFS was 25 months
(95% CI: 10–40) with a median follow-up time of 60 months
(95% CI: 54–67). Forty-one (71%) patients had an event after
CLM resection (liver metastases (n=16); lung metastases (n=7);
recurrence other sites than liver and lung (n=5); recurrence at
multiple sites (n=8); other cancer (n=4); death without cancer
recurrence (n=1)). Variables associated with OS and PFS in this
cohort were similar to previously published results from the
OSLO-COMET trial (7), and there were no associations between
T-cell densities or immune score and long-term outcome
(Supplementary Table 4).DISCUSSION
In this ancillary study from the OSLO-COMET trial, T-cell
densities (Ttot, CTL, TH and Tregs) were quantified using IHCTABLE 1 | Clinicopathological variables.
Variable N (%)
Gender Male 32 (55)
Female 26 (45)
pCRC
Age Median (IQR) 66 (60–72)
TNM
T T1-T2 3 (5)
T3 43 (74)
T4 12 (21)
N N0 24 (41)
N1 19 (33)
N2 15 (26)
M M1 21 (36)
Histological grading Low grade 51 (88)
High grade 6 (10)
Not classified 1 (2)
Anatomical location Right side 16 (28)
Left side/rectum 42 (72)
Immune score Low 0 3 (5)
1 4 (7)
2 12 (21)
High 3 13 (22)
4 26 (45)
CLM
Performance status ECOG 0 42 (72)
1–2 16 (28)
Clinical risk score Low 0 7 (12)
1 18 (31)
2 19 (33)
High 3 13 (22)
4 1 (2)
5 0










Response (RECIST 1.1) Partial response 14 (50)
Stable disease 10 (36)
Progressive
disease
4 (14)pCRC, primary colorectal cancer; T, tumor; N, lymph node metastases; M, distant
metastases; CLM, colorectal liver metastases; ECOG, The Eastern Cooperative
Oncology Group performance status; CEA, carcinoembryonic antigen; NACT,
neoadjuvant chemotherapy; RECIST, response evaluation criteria in solid tumors.June 2021 | Volume 11 | Article 671629
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resectable CLM, of which only one was classified as MSI. The low
MSI frequency is well in line with the majority (72%) of the
primary tumors being located in the left colon, where MSI is
typically much less common than in right-sides cases (2% vs
17%) respectively (24). This is also in accordance with previous
molecular findings in a subset of this cohort showing lowFrontiers in Oncology | www.frontiersin.org 5frequency of BRAF mutated cases and a dominance of the
CMS2 subtype (7). A high concordance was previously
demonstrated between the primary tumor and corresponding
metastases for the most common driver mutations and MSI
status in CRC, suggesting that the primary site adequately reflects
the individual patient’s disease with respect to these parameters
(25, 26). In contrast, T-cell densities in pCRC and matched CLMFIGURE 1 | Total T-cell densities in in tumor adjacent colorectum (NCr) and liver (NLi), intratumor (IT) and invasive margin (IM) in primary colorectal cancer (pCRC)
and colorectal liver metastases (CLM). Representative immunohistochemistry images show T-cell densities (Ttot; CD3+). Images were acquired at 4× magnification
and the black line represents 0.2 mm. The following regions are shown: (A) NCr; (B) IT pCRC; (C) IM pCRC; (D) NLi; (E) IT CLM; (F) IM CLM. (G, H) show dot
density plots comparing pairwise total T-cell densities (Ttot) in the same regions. The black lines represent median values. Only significant differences are shown.
*P-value < 0.05; ****P-value < 0.0001.June 2021 | Volume 11 | Article 671629
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when matched data have been available, results have either been
conflicting (14, 16), or the focus has remained on reporting
group comparisons (18). In our cohort, the correlation between
pCRC and CLM from the same individual was extremely low for
total T-cell densities, and for the investigated T-cell subtypes,
and consequently also for the calculated immune score. This
could possibly be related to the distinct differences in T-cell
densities and T-cell composition in NCr and NLi visualizing a
difference in immune function in the colorectum compared to
the liver. The pCRC immune contexture therefore does not seem
to be predictive for CLM, which should be kept in mind as tumor
infiltrating T-cells are emerging as a potential predictive
biomarker for response to immune therapy.
A striking accumulation of T-cells in the IM regions was
observed, particularly in CLM, contrasting the exceptionally low
T-cell densities detected in NLi. The findings are in accordance
with previous reports and likely represent recruitment of T-cells to
the tumor site in both the colorectum and liver (12, 13, 18). The
prominent differences in T-cell densities between the IM and IT
regions demonstrate an inefficiency of penetration into the tumor
regions, which could be influenced by a number of factors, such asFrontiers in Oncology | www.frontiersin.org 6immunosuppressive signals in the extracellular matrix, lack of T-
cell activation by antigen presenting cells, and the presence of
immunosuppressive immune cells and chemokines (27, 28). The
median IT CTL density of our pCRC samples was very similar to
the CTL density previously reported for MSS pCRC tumors (106
cells/mm3 vs ~100 cells/mm3, respectively) (29), which is in line
with all our cases, except one, beingMSS. Interestingly, the IT CTL
densities of pCRC and CLM were similar in our study, and only
half of the CTL density found in MSI pCRC (29), suggesting that
the immunosuppressed and immune excluded features of MSS
pCRC were preserved in CLM (5). We previously demonstrated a
transient increase in T-cell densities in CLM after neoadjuvant
chemotherapy and also that differentially expressed genes related
to “Dendritic Cell Maturation” and “Cellular Movement, Immune
Cell Trafficking” were up-regulated in the patients who had
neoadjuvant chemotherapy compared to patients that had no
chemotherapy in the OSLO-COMET cohort (6, 7). Based on
these results, we have initiated the ongoing “Colorectal Cancer
METastasis - Shaping Anti-tumor IMMunity by Oxaliplatin”
(METIMMOX) trial (NCT03388190), where cytotoxic
chemotherapy is being studied as a potential means to overcome
immune suppression in MSS mCRC.
The highest TH : CTL ratios were found in the IT region of
pCRC, followed by the IT of CLM and IM of pCRC/CLM.,
contrasting ratios close to 1 in the adjacent tumor tissues. A highTABLE 2 | Median T-cell densities (cells/mm2) in tumor adjacent tissue, IT and IM in pCRC and CLM.
NCr pCRC NLI CLM
IT IM IT IM
Ttot 533 (371–764) 485 (284–706) 1244 (933–1749) 221 (122–319) 340 (184–569) 2838 (2292–3841)
CTL 232 (146–357) 106 (51–196) 497 (315–720) 121 (68–213) 101 (49–222) 1084 (763–1423)
TH 287 (188–422) 353 (191–481) 772 (614–1004) 77 (51–123) 199 (115–397) 1904 (1454–2715)
Tregs 58 (41–103) 144 (74–224) 223 (163–360) 3 (0–5) 43 (21–85) 229 (123–377)June 2021 | Volume 1pCRC, primary colorectal cancer; CLM, colorectal liver metastases; NCr, tumor adjacent colon and rectum; NLI, tumor adjacent liver tissue; IT, intratumor; IM, invasive margin; Ttot, total
amount of T-cells (CD3+), CTL, cytotoxic T-cells (CD8+); TH, helper T-cells (CD4+); Tregs, regulatory T-cells (FOXP3+).FIGURE 2 | Dot density plots showing ratios of helper T-cells to cytotoxic
T-cells (TH : CTL) in tumor adjacent colorectum (NCr) and liver (NLi), intratumor
(IT) and invasive margin (IM) in primary colorectal cancer (pCRC) and
colorectal liver metastases (CLM). The black lines represent median values.
The dashed line indicates a ratio of 1.0. Regions are compared pairwise using
the Mann-Whitney U test and only significant differences are shown.
***P-value < 0.001; ****P-value < 0.0001.FIGURE 3 | Dot density plots showing ratios of regulatory T-cells to helper
T-cells (Treg : TH) in tumor adjacent colorectum (NCr) and liver (NLi), intratumor
(IT) and invasive margin (IM) in primary colorectal cancer (pCRC) and colorectal
liver metastases (CLM). Regions were compared pairwise using the Mann-
Whitney U test/Wilcoxon signed rank tests. Pairwise comparisons were all
significant with a P-value < 0.0001 (Supplementary Tables 1, 2).1 | Article 671629
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in pCRC and with poor prognosis in both pCRC and CLM
(30–32). The interplay between T-cell subtypes has been
recognized as important in controlling tumor growth, with TH
subsets orchestrating adaptive immune responses and CTL
exer t ing c la s s i c ant i - tumor e ff ec t s (33 , 34) . The
immunosuppressive Treg subtype of TH cells (35) exhibited the
lowest density of the investigated T-cell subtypes in most regions,
but the relative proportion of Tregs to TH was highly variable. In
the NCr Tregs constituted about 20% of TH, which is in agreement
with previous reports, showing that Tregs are quite abundant in
the colorectum (36). In the IT pCRC region the Treg: TH ratio was
particularly high, with Tregs constituting 44% of TH cells. The
immune inhibitory effect of Tregs on CTL and TH is exerted by
several mechanisms, for instance by expression of immune check-
point proteins, such as cytotoxic T-lymphocyte–associated antigen
4 and programmed death-ligand 1 (PD-L1), in addition to
secreting immunosuppressive cytokines, such as interleukin-10,
prostaglandin E2, and transforming growth factor b (37, 38).
Interestingly, PD-L1 was expressed in only 1/92 CLM cases from
the OSLO-COMET trial (including all the CLM cases in this
study) (6). The high tumor TH : CTL and Treg : TH ratios are in
line with all the investigated cases having developed metastatic
disease, and underline the role of TH in the immune suppressive
tumor microenvironment of pCRC and CLM. The interesting
findings derived from these analyses, particularly regarding T-cell
subsets, underline the limitation related to use of only four T-cell
markers. Efforts to further characterize the TH subsets and other
immune cells, such as macrophages and neutrophils, in CLM are
warranted. For such analyses more high-throughput methods
should be employed.
Using the immune score classification developed by Galon
et al. (8), the majority (67%) of pCRC in our cohort had a
favorable immune score. This finding is somewhat unexpected,
since the entire cohort was composed of pCRC cases that
developed CLM (76% within the first year of pCRC surgery),Frontiers in Oncology | www.frontiersin.org 7and in contrast to previous reports where a high immune score in
pCRC was associated with a low disease recurrence rate (8, 39).
The lack of agreement could reflect an intended “selection bias”
based on clinical assessment of CLM resectability in the OSLO-
COMET trial, resulting in differences between the pCRC cohorts.
When the immune score criteria were applied to the metastatic
tumors, 59% of the CLM were classified in the high immune
score group. However, as previously noted, concordance between
individual immune score in pCRC and matched CLM was poor
and there were no associations between CLM T-cell subtype
densities or calculated immune score and long-term outcome. In
contrast to our results, some studies have demonstrated
associations between a high CLM immune score and a
favorable outcome after CLM resection (12–14). Regretfully,
although our cohort was sizable in the context of analyzing the
immune microenvironment, it was not planned or powered for
detection of small differences in outcome. Taken together, there
seems to be a need for further studies to clarify the utility of CLM
T-cell density assessment as a tool for predicting prognosis after
metastasis surgery. If the role of T-cell quantification could be
established in this context, it could be a useful asset for treatment
selection in CLM patients.
In this study of matched pCRC and CLM samples,
accumulation of T-cells in the IM regions with low penetration
to the IT regions combined with high TH : CTL and Treg : TH
ratios pointed to an immune suppressive microenvironment.
With the observed low correlation between tumor T-cell
infiltration in pCRC and matched CLM, analysis of T-cells in
pCRC is clearly not a valid biomarker for CLM. This is of
particular importance in non-resectable CLM, where resection
specimens will not be available. For the non-resectable setting,
establishment of methods that require less material for
assessment of T-cell infiltration is warranted, using for instance
sequencing based approaches. Patient cohorts with available
resection specimens, such as ours, may be useful for validation
of novel analytical approaches.A B
FIGURE 4 | Representative scatter plots investigating correlation between T-cell densities (cells/mm2) in the invasive margin (IM) of primary colorectal cancer (pCRC;
x-axis) and colorectal liver metastases (CLM; y-axis). The black line represents the regression line with a 95% confidence interval. (A) Total T-cell densities in IM,
correlation coefficient (R2) = 0.07. (B) Cytotoxic T-cell densities in IM, R2 = 0.18.June 2021 | Volume 11 | Article 671629
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